NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

01-C-0038

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Children;
Adults who are or may become unable to consent

Keywords

Tumor;
Viruses;
HIV;
KSHV;
AIDS;
Natural History

Recruitment Keyword(s)

None

Condition(s)

HIV;
Kaposi's Sarcoma;
Lymphomas;
Multicentric Castleman's Disease;
Primary effusion lymphoma

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

BACKGROUND:

-A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer.

-This protocol provides a mechanism to affect a variety of such studies.

OBJECTIVES:

-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.

ELIGIBILITY:

-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.

DESIGN:

-Up to 999 subjects will be enrolled in this study.

-Blood samples may be collected at the initial visit, and at follow-up visits.

-Other fluids/excretions may be collected (such as urine, saliva, semen, and stool).

-Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants.

-Specific risks will be described in a separate consent to be obtained at the time of the biopsy.

-Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Age 18 years or older.

-ECOG performance status less than or equal to 3.

At least one of the following:

--Exposure risk to HIV, KSHV, or HPV

--HIV seropositive

--KSHV seropositive

--EBV seropositiv

--HTLV-1 seropositive

NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease), this is sufficient to meet this criterion for eligibility.

-Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma

-Cervical or anal intraepithelial lesion

-Ability of subject to understand and the willingness to sign a written informed consent document. Participants could have a witness signature if they are either blind or illiterate, etc.

EXCLUSION CRITERIA:

Inability to provide informed consent.


--Back to Top--

Citations:

Davis DA, Dorsey K, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry. 1996 Feb 20;35(7):2482-8. doi: 10.1021/bi951525k. PMID: 8652592.

Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL, Yarchoan R. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. Biochem J. 2000 Mar 1;346 Pt 2(Pt 2):305-11. PMID: 10677347; PMCID: PMC1220854.

Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 1999 Oct 22;13(15):2003-12. doi: 10.1097/00002030-199910220-00002. PMID: 10546852.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Robert Yarchoan, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CLINICAL CENTER BG RM 6N106
10 CENTER DR
BETHESDA MD 20892
(240) 760-6075
robert.yarchoan@nih.gov

Anaida Widell
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 13C438
10 Center Drive
Bethesda, Maryland 20814
(240) 760-6074
anaida.widell@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937
ncimo_referrals@mail.nih.gov

Clinical Trials Number:

NCT00006518

--Back to Top--